B. Riley analyst Kalpit Patel downgraded Longboard Pharmaceuticals (LBPH) to Neutral from Buy with a price target of $60, up from $45, after the company entered into a definitive agreement with Lundbeck to be acquired for $2.6B, or $60 per share. The firm views the acquisition price as “highly reasonable.” It does not foresee any significant hurdles for the acquisition to be completed. Riley remains bullish on Geron (GERN) and believes it stands out as the most likely candidate for a buyout following Longboard, “as it meets key biopharma acquisition criteria.”
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
- Make smarter investment decisions with TipRanks' Smart Investor Picks, delivered to your inbox every week.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on LBPH:
- Lundbeck Acquires Longboard Pharmaceuticals for $2.6 Billion
- Truist downgrades Longboard to Hold on Lundbeck deal announcement
- Longboard Pharmaceuticals downgraded to Hold from Buy at Truist
- Longboard Pharmaceuticals downgraded to Neutral from Outperform at Baird
- M&A News: Lundbeck to Acquire Longboard (NASDAQ:LBPH) for $2.6B